KNSA — Kiniksa Pharmaceuticals International Share News
0.000.00%
Last trade - 00:00- $6.24bn
- $5.71bn
- $677.56m
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises
Kiniksa Q4 revenue rises on ARCALYST sales
Brief: Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharma raises ARCALYST's 2025 sales forecast
Kiniksa Pharmaceuticals International PLC reports results for the quarter ended June 30 - Earnings Summary
Drugmaker Kiniksa's Q2 revenue jumps 52%
Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis
U.S. STOCKS ON THE MOVE-MeiraGTx, CervoMed, Natgas companies
U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx
U.S. STOCKS ON THE MOVE-Xpeng, D-Wave Quantum, Trinity Biotech
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Microsoft
Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty
Brief: Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September 30 - Earnings Summary
Brief: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results And Recent Portfolio Execution
Brief: Kiniksa Pharmaceuticals Says Board Size Increases From Nine To Ten